Overview

Study of NDI-034858 in Subjects With Moderate to Severe Plaque Psoriasis

Status:
Recruiting

Trial end date:
2022-10-31

Target enrollment:

Participant gender:

Summary

This is a Phase 2b, randomized, multicenter, double-blind, placebo-controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in subjects with moderate to severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI-034858 and explore the immune response to NDI-034858 in subjects with moderate to severe plaque psoriasis.

Phase:

Phase 2

Details

Lead Sponsor:

Nimbus Lakshmi, Inc.

Collaborator:

Innovaderm Research Inc.